Presently, over 150 neoantigen targeted therapies are being evaluated for advanced cancer indications

The use of neoantigens in therapy has demonstrated the ability to elicit a strong T cell mediated immune response. Several therapy candidates are being investigated both as monotherapies and in combination with various immune checkpoint inhibitors, such as atezolizumab, durvalumab, ipilimumab, and nivolumab. Of these, certain pipeline candidates have already entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.

To order this 320+ page report, which features 110+ figures and 140+ tables, please visit this link  

The USD 3 billion (by 2030) financial opportunity within the neoantigens market has been analyzed across the following segments:

§  Type of target disease indication

§  Bone cancer

§  Colorectal cancer

§  Gynecological cancer

§  Non-small cell lung cancer

§  Renal cell carcinoma

§  Other cancers

§  Type of neoantigens

§  Personalized neoantigens

§  Off-the-shelf neoantigens

§  Type of immunotherapy

§  Dendritic cell vaccines

§  DNA / RNA-based vaccines

§  Protein / peptide-based vaccines

§  TIL-based therapies

§  Route of administration

§  Intradermal

§  Intravenous

§  Subcutaneous

§  Other routes

§  Key geographical regions

§  North America

§  Europe

§  Rest of the World

The report features inputs from eminent industry stakeholders, according to whom neoantigen targeted therapies are expected to be the next big step in cancer immunotherapy. Similar to CAR-T cell therapies, these therapies have, so far, demonstrated significant therapeutic potential and promising clinical outcomes. The report includes detailed transcripts of discussions held with the following experts:

§  Gabriel Nistor (Chief Science Officer, AIVITA Biomedical)

§  Ella Sorani (Vice President Research and Development, BioLineRx)

§  Heinz Lubenau (Chief Operating Officer & Co-founder, VAXIMM)

The Neoantigen Targeted Therapies, 2019-2030 report features the following companies, which we identified to be key players in this domain:

§  Bavarian Nordic

§  Genocea Biosciences

Press Release: Variation 3 (Format 4)

§  Gradalis

§  Immunicum

§  Immunovative Therapies

§  Iovance Biotherapeutics

§  Medigene

§  Neon Therapeutics

§  Precision Biologics

§  Vaxon Biotech

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. Company Profiles: Neoantigen Targeted Therapies

6. Publication Analysis

7. Patent Analysis 

8. Partnerships and Collaborations

9. Funding and Investment Analysis

10. Market Forecast and Opportunity Analysis

11. Concluding Remarks

12. Executive Insights

13. Appendix 1: Tabulated Data

14. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/neoantigen-targeted-therapies-market-2019-2030/257.html

Contact Details:

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com